Skin Inflammation

Inflammatory skin disorders include a wide range of conditions ranging in severity, from mild itching to more serious complications. Concurrently, the increasing use of immunomodulatory drugs for the treatment of other autoimmune diseases has seen a rise in the numbers of Adverse Drug Reactions which most commonly include skin eruptions.


Using a human skin explant system Aquila is able to generate an immunological signature of the effects that immunomodulatory compounds may have when injected into human skin. This system has the potential to be manipulated for a variety of purposes.



Psoriasis is a common, chronic, relapsing/remitting, immune-mediated systemic disease affecting approximately 4% of the general population. It is characterised by lesions of the skin, typically as itchy red, scaly patches or plaques. Lesions have infiltration of immune cells in the dermis and epidermis and massively altered epidermis structure. Psoriasis is believed to result from the dysregulated interplay between keratinocytes and infiltrating immune cells, although the exact cause is unknown.

Skin lesions seen in psoriasis vary in severity between individuals from minor localized patches to complete body coverage. Around 20-30% of patients with psoriasis will develop psoriatic arthritis which affects articular joints. Current therapies for psoriasis and psoriatic arthritis are crude and ineffective, necessitating the requirement for better preclinical models for early drug development.

Aquila is developing standard and novel models in collaboration with interested parties to include:

  • Topical Skin Inflammation
  • Systemic transgenic mouse models
  • Human skin culture from psoriatic patients

Please contact us to find out more about our human skin explant system or Inflammatory models.


We’d be happy to discuss any service or product you may be interested in.

Aquila BioMedical Ltd.
Nine, Edinburgh BioQarter
9 Little France Road
EH16 4UX

Tel: +44 (0) 131 658 5164